21 results
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 May 24
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:15am
(NMRA-140) is a highly selective, novel, once-daily kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
of the Kappa Opioid Receptor (NMRA-140) for the treatment of major depressive disorders and achievement of certain sales-based milestones related … trial for an antagonist of the Kappa Opioid Receptor (NMRA-140) for the treatment of major depressive disorders and achievement of
certain sales
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of major depressive disorder (MDD … and selective antagonist for KOR and, in preclinical studies, has shown more than 300-fold selectivity over the Mu opioid receptor (MOR). Selectivity for KOR over
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7:08am
-daily kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD and other neuropsychiatric disorders. The KOR … physical dependence with navacaprant.
Navacaprant did not demonstrate properties associated with risks of opioid-related abuse in several mode of action
8-K
EX-99.1
mi48ixnjkno36bhl3
8 Jan 24
Regulation FD Disclosure
8:32am
10-Q
qx405ri
1 Nov 23
Quarterly report
4:05pm
8-K
EX-99.1
0wg1gs
1 Nov 23
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:01pm
424B4
2vcrk9q6 r52v81q3ri9
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
xonhx3lvgi0o3pj
11 Sep 23
IPO registration (amended)
6:07am
S-1
2kga1x6m6bmntx99
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.5
alnf4sd9 ciy4lk
25 Aug 23
IPO registration
5:03pm
DRS/A
qyrogc
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
xax wbb6v59
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
njb j2tyt
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
oom2wvnb lfz8
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
eidgftffj
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
wj49ea39u8 45n
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
csq9321keuaajp6cumda
23 Dec 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.5
euo0aof075xmndm5bq4l
23 Dec 21
Draft registration statement (amended)
12:00am